Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 3Phase 3 2Phase NA 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × chiauranib × Clear all
NCT05271292 2024-07-16

SCLC

Chipscreen Biosciences, Ltd.

Phase 1/2 Recruiting
36 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03974243 2022-03-09

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
9 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03245190 2021-06-18

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03166891 2020-01-18

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
25 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡